Mylan, Glenmark, Cadila, Teva to sell generic Mobic for osteoarthritis

By Elaine Rigoli

Tampa, Fla., July 20 - Mylan Laboratories, Inc., Glenmark Pharmaceutical Inc., Cadila Healthcare, Inc. and Teva Pharmaceutical Industries Ltd. have received Food and Drug Administration approval to market Meloxicam tablets, 7.5 mg and 15 mg.

Meloxicam tablets are indicated for the relief of the signs and symptoms of osteoarthritis. They are the AB-rated generic equivalent of Boehringer Ingelheim's Mobic tablets, which had annual U.S. sales of about $1 billion.

Mylan is a pharmaceutical company based in Canonsburg, Pa.

Glenmark is a pharmaceutical company based in Mahwah, N.J.

Cadila, a division of Zydus Cadila, is a pharmaceutical company based in Princeton, N.J.

Teva is a pharmaceutical company with headquarters in Jerusalem, Israel.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.